Interrelationships between sclerostin, secondary hyperparathyroidism, and bone metabolism in patients on hemodialysis.

Yosuke NakagawaHirotaka KomabaNaoto HamanoHisae TanakaTakehiko WadaHiroaki IshidaMichio NakamuraHiroo TakahashiYuichiro TakahashiToru HyodoMiho HidaTakao SugaTakatoshi KakutaMasafumi Fukagawa

Published in: The Journal of clinical endocrinology and metabolism (2021)

These findings suggest that in patients undergoing dialysis, sclerostin has only a limited role in bone metabolism and may not mediate the effect of PTH on bone turnover.

Keyphrases

end stage renal disease
bone mineral density
chronic kidney disease
peritoneal dialysis
patients undergoing
postmenopausal women
bone loss
soft tissue
newly diagnosed
ejection fraction
bone regeneration
prognostic factors
patient reported